Connect your AI

Royalty Pharma RPRX Total Liabilities

Total Liabilities at other companies

Ligand PharmaceuticalsLGND

$3.94M-96.4%

BridgeBio PharmaBBIO

$3.64B+44.4%

Rigel PharmaceuticalsRIGL

$104.71M-33.5%

Roivant SciencesROIV

$416.28M+66.7%

ALN

Alnylam PharmaceuticalsALNY

$4.2B-2.6%

Ionis PharmaceuticalsIONS

$2.55B+8.6%

Other financials

Income statement

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

Operating cash flow$718.2M+20.5%

Valuation

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Royalty Pharma's total liabilities?: Royalty Pharma (RPRX) reported total liabilities of $9.88B in Q1 2026.
How has Royalty Pharma's total liabilities changed year-over-year?: Royalty Pharma's total liabilities increased by 26.3% year-over-year, from $7.82B to $9.88B.
What is the long-term trend for Royalty Pharma's total liabilities?: Over 5 years (2020 to 2025), Royalty Pharma's total liabilities has grown at a 10.1% compound annual growth rate (CAGR), from $6.12B to $9.91B.
What does total liabilities mean?: The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.